4SCAR T cells is named as an intervention in 3 current clinical trials in our China register. None are recruiting at the moment. All registered phases are Phase 1/2. The lead sponsor is Shenzhen Geno-Immune Medical Institute. The most-studied condition is Autoimmune Diseases.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Multi-4SCAR-T Therapy Targeting Breast Cancer
NCT04430595 · ClinicalTrials.gov ↗ · Breast Cancer
|
Phase 1/2 | Not yet open | Shenzhen Geno-Immune Medical Institute | China |
|
CAR-T Cells Targeting Autoimmune Diseases
NCT05459870 · ClinicalTrials.gov ↗ · Autoimmune Diseases
|
Phase 1/2 | Not yet open | Shenzhen Geno-Immune Medical Institute | China |
|
Autoimmune Disease Treatment With Mesenchymal Stem Cells (MSCs) and CAR-T Cells
NCT06435897 · ClinicalTrials.gov ↗ · Autoimmune Diseases
|
Phase 1/2 | Not yet open | Shenzhen Geno-Immune Medical Institute | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Shenzhen Geno-Immune Medical Institute | 3 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 3 | 0 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our China register name 4SCAR T cells as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 3 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Shenzhen Geno-Immune Medical Institute. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how 4SCAR T cells works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how 4SCAR T cells works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists 4SCAR T cells (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.